ResMed annual profit flat at $US352m

Sleep disorder treatment firm ResMed remains confident of its long-term strategy and outlook.

Sleep disorder treatment firm ResMed’s flat annual profit has come in flat but it’s confident of its long-term strategy and outlook.

ResMed’s (RMD) annual profit for the year to June 30, was $US352.4 million ($A468.9 million), slightly lower than 2015’s $352.9 million, while revenue was up 10 per cent at $US1.8 billion.

“We finished the year with double-digit constant currency revenue growth, fuelled by solid performance in masks, devices, and our first quarter of software-as-a-service revenue from Brightree,” chief executive Mick Farrell said.

AAP